INTRODUCTION
============

In Korea, gastric cancer (GC) is the second most common cancer.[@b1-gnl-11-635] Because GC is not a homogenous disease, the prognosis of patients with GC is diverse and is currently based on histology and tumor stage. *Helicobacter pylori* infection is closely associated with GC carcinogenesis. The International Agency for Research on Cancer, a subdivision of the World Health Organization (WHO), recognizes *H. pylori* as a group I carcinogen for gastric carcinoma.[@b2-gnl-11-635] However, there are also GCs which are not related to *H. pylori* infection. *H. pylori*-negative GCs comprise 2% to 10% of all GCs.[@b3-gnl-11-635] Previous studies suggest that a negative *H. pylori* status is correlated with more advanced disease than a positive *H. pylori* status.[@b4-gnl-11-635],[@b5-gnl-11-635] In addition, there are some reports that a negative *H. pylori* status is a prognostic factor of poor outcome in patients with GC after gastrectomy.[@b6-gnl-11-635]--[@b8-gnl-11-635] Meimarakis *et al*.[@b6-gnl-11-635] reported that relapse-free and overall survival of patients with positive *H. pylori* status are significantly higher than in patients with negative *H. pylori* status after curative resection. They evaluated the *H. pylori* status of 166 patients after curative resection to treat GCs. Among them, 41 patients (24.7%) were negative for *H. pylori*. And, they suggest that tumor-specific immune responses might be downregulated in patients who are negative for *H. pylori*.[@b6-gnl-11-635] In Korea, there was a report that a negative *H. pylori* status is the most significant independent factor to predict poor prognosis in patients with locally advanced GC treated with adjuvant chemotherapy after curative surgery.[@b8-gnl-11-635] Kang *et al*.[@b8-gnl-11-635] investigated the *H. pylori* infection status in 274 locally advanced GC patients. Of these, 108 patients (39.4%) were negative for *H. pylori*. In this study, we aimed to investigate the *H. pylori* infection status and evaluate the clinical significance of *H. pylori* infection for patients with GC after they received curative surgery.

MATERIALS AND METHODS
=====================

1. Patients
-----------

Between February 1996 and December 2012, 314 patients were tested for *H. pylori* infection using a rapid urease test at least 2 months after curative resection to treat GC at Severance Hospital. Curative resection was defined according to the Japanese GC treatment guidelines.[@b9-gnl-11-635] Patients were regarded as positive for *H. pylori* if they were positive by the rapid urease test. Patients were evaluated in terms of age, sex, history of chemotherapy or radiotherapy, and survival. The investigated variables also included tumor location, tumor size, depth of tumor invasion, lymph node metastasis, histological classification, lymphovascular invasion, and perineural invasion. The following patients were excluded: (1) patients that received a total gastrectomy; (2) patients who were not given the rapid urease test after gastrectomy; (3) patients with distant metastasis (M1); (4) patients that received chemotherapy prior to gastrectomy; and (5) patients who received *H. pylori* eradication therapy before curative resection. The pathologic stage of the tumor was determined according to the standards set by the seventh American Joint Committee on Cancer (AJCC).[@b10-gnl-11-635] The Institutional Review Board of Severance Hospital approved this study.

2. Follow-up
------------

During the first 2 years after gastrectomy, patients were assessed every 3 months by clinical examination, routine blood tests, and tumor markers; abdominal computed tomography and endoscopy were performed every 6 months. During the next 3 years, patients were examined every 6 months and received endoscopy every 12 months.

3. Statistical analysis
-----------------------

The chi-square and Fisher exact tests were used to compare the clinicopathological factors between groups based on their *H. pylori* status. The t-test was used for noncategorical variables in the intergroup comparisons of the clinicopathological characteristics. Results were considered significant if p\<0.05. For the multivariate analysis, variables with p\<0.05 on the univariate analysis and clinically important variables including age, gender, tumor size, and tumor stage were entered. The Kaplan-Meier method was used to determine the overall survival rates and the log-rank test was used to analyze differences in the survival curve. A Cox proportional hazards model and multivariate analyses were used to determine the risk assessment. All statistical analyses were performed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

1. Association among clinicopathological characteristics and *H. pylori* infection
----------------------------------------------------------------------------------

Two hundred and ten men and 104 females were enrolled in this study. Their mean age was 55.4 years (standard deviation, ±11.5). There were no differences in age, gender, tumor size, tumor location, T stage, N stage, AJCC stage, WHO classification, Lauren classification, lymphovascular invasion, and perineural invasion between the *H. pylori*-positive and -negative groups ([Table 1](#t1-gnl-11-635){ref-type="table"}).

2. Association between overall survival and *H. pylori* infection status
------------------------------------------------------------------------

The median duration for follow-up assessments was 93.5 months (range, 18 to 208 months). The 10-year overall survival rate was 95.3%, 96.5%, and 69.8% for stage I, II, and III cancers, respectively. In the univariate analysis, the 10-year overall survival rate was 95.1% and 91.5% for patients positive and negative for *H. pylori*, respectively (p=0.030) ([Fig. 1](#f1-gnl-11-635){ref-type="fig"}). When examining the different stages of cancer, the overall survival rate for patients negative for *H. pylori* was lower than those who tested positive for *H. pylori* ([Fig. 2](#f2-gnl-11-635){ref-type="fig"}). In the univariate analysis, old age and negative for *H. pylori* infection status were correlated with lower overall survival rate ([Table 2](#t2-gnl-11-635){ref-type="table"}). We performed subgroup analyses based on the different clinicopathological factors. Old age, lower third location, advanced T stage (T3/4), and negative for *H. pylori* infection status were correlated with poor overall survival rates ([Table 3](#t3-gnl-11-635){ref-type="table"}). In the multivariate analysis, old age (hazard ratio, 3.02; 95% confidence interval, 1.22 to 7.47; p=0.017) and negative *H. pylori* status (hazard ratio, 2.95; 95% confidence interval, 1.14 to 7.66, p=0.026) were independent prognostic factors of poor overall survival ([Table 4](#t4-gnl-11-635){ref-type="table"}).

3. Association between disease-specific survival and *H. pylori* status
-----------------------------------------------------------------------

We analyzed the disease-specific survival rates between *H. pylori*-negative and -positive GC patients. The 10-year disease-specific survival rates for patients with negative and positive *H. pylori* status were 93.9% and 95.5%, respectively ([Fig. 3](#f3-gnl-11-635){ref-type="fig"}). In addition, we evaluated the disease-specific survival rates according to the T and N stages. For patients with T2--4 stages of disease, the disease-specific survival rate for patients with a negative *H. pylori* status was significantly lower than in those with a positive *H. pylori* status ([Fig. 4](#f4-gnl-11-635){ref-type="fig"}).

DISCUSSION
==========

According to Correa's hypothesis, *H. pylori* infection is closely associated with the development of GC.[@b11-gnl-11-635] However, there are few reports about the role of *H. pylori* infection in GC patients after curative surgical resection. Currently, there are no guidelines regarding the treatment of *H. pylori* infection after gastrectomy and the effects of treatment are unknown. To our knowledge, Lee *et al*.[@b4-gnl-11-635] first reported that *H. pylori* seropositive GC patients showed a better prognosis after gastrectomy. There are two prospective studies that investigated the prognostic role of *H. pylori* infection.[@b6-gnl-11-635],[@b7-gnl-11-635] In Germany, Meimarakis *et al*.[@b6-gnl-11-635] showed that a negative *H. pylori* status is an independent prognostic factor of poor relapse-free and overall survival in patients with GC after curative surgery. In patients with early-stage GC, the overall survival of patients who were positive for *H. pylori* was significantly higher than those who were negative.[@b6-gnl-11-635] They evaluated *H. pylori* infection by bacterial culture, serologies, and histologies. Previous study reported that patients with a negative for *H. pylori* infection status have a worse prognosis after curative surgery. *H. pylori* infection was determined by polymerase chain reaction analysis for the *vacA* gene and a serology of *H. pylori* and CagA antibodies. *H. pylori* infection is correlated with long-term survival of patients with early as well as advanced pT disease.[@b7-gnl-11-635] In this study, the 10-year overall survival of *H. pylori*-negative GC patients after curative resection was significantly lower than *H. pylori*-positive GC patients, which is similar to data observed in the previous studies. The prognostic impact of a negative for *H. pylori* infection status was significant for some of the subgroups such as old age, lower third location, and advanced T stage. In the multivariate analysis, old age and negative for *H. pylori* infection status were independent prognostic factors for poor overall survival of GC patients after curative surgery. We assessed *H. pylori* status using a rapid urease test 2 months after the curative surgery for GC.

The reason that negative for *H. pylori* infection status is correlated with poor prognosis in GC patients after curative surgery is not well known. There are several possible explanations. Immune responses caused by *H. pylori* could evoke antitumor immunity. A previous report shows that patients negative *H. pylori* status have more numbers of cells expressing OX40 in cancerous tissue than those positive *H. pylori* status. OX40 directly modulates immune suppression mediated by regulatory T cells.[@b12-gnl-11-635] Thus, the authors contend that tumor-specific immune responses are downregulated in patients without *H. pylori* infection, in consequence of increased infiltration of OX40 positive cells.[@b6-gnl-11-635] CD4^+^ and CD8^+^ T cells are increased in the presence of *H. pylori*, suggesting that tumor antigens might induce stronger immune reactions during *H. pylori* infection.[@b13-gnl-11-635] Further, Xue *et al*.[@b14-gnl-11-635] assume that *H. pylori* components either mimic or bind to specific receptors or surface molecules on gastric epithelial cells, which could result in autoantibodies. These autoantibodies could recognize GC cells which may display the mimic *H. pylori* antigens.[@b14-gnl-11-635]

A second plausible reason is the part of microsatellite instability (MSI) in *H. pylori*-positive GC. A previous study showed that patients with MSI are more likely to have active *H. pylori* infection than those with stable tumors.[@b15-gnl-11-635] Further, previous study reported that alterations in MSI is associated with a higher rate of *H. pylori* infection, a better postoperative survival, and less lymph node metastasis.[@b16-gnl-11-635] However, some authors argue whether *H. pylori* infection status has prognostic value or not. They suggest that negative for *H. pylori* infection status might be correlated with more advanced tumor status.[@b5-gnl-11-635],[@b17-gnl-11-635] In this study, there were no differences in the clinicopathological characteristics between the *H. pylori*-positive and -negative groups.

Our study has some limitations. First, this is a retrospective study and *H. pylori* infection was evaluated using a rapid urease test of the remnant stomach during the endoscopic examinations. Therefore, patients who underwent total gastrectomy because of proximally located GC were excluded from this study. And, we could not evaluate *H. pylori* infection by histology, urea breath test, and serology. Second, the 10-year overall survival of patients was 93.1%, which is quite high. This is mainly due to the high proportion of patients with stage I cancer (70.7%). To our knowledge, our study was the largest reported that analyzed the association between *H. pylori* infection and prognosis of GC patients who underwent curative surgery with long-term follow-up. In this study, patients negative for *H. pylori* infection were significantly associated with poor prognosis.

In conclusion, negative for *H. pylori* infection status appeared to be an indicator of poor prognosis in GC patients treated with curative surgery. Further prospective studies that include patients with advanced stages of cancer are needed to examine the effect of *H. pylori* status on the prognosis of GC patients after curative surgery.
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###### 

Association between Clinicopathologic Findings and *Helicobacter pylori* Status

  Variable                     *H. pylori*   p-value      
  ---------------------------- ------------- ------------ -------
  Age, yr                      54.4±10.8     56.2±12.0    0.174
  Sex                                                     0.807
   Male                        87 (68.0)     123 (66.1)   
   Female                      41 (32.0)     63 (33.9)    
  Tumor size, mm               29.2±19.9     27.6±19.3    0.488
  Tumor location                                          1.000
   Middle third                48 (37.5)     71 (38.2)    
   Lower third                 80 (62.5)     115 (61.8)   
  T stage                                                 0.490
   T1                          79 (61.7)     130 (69.9)   
   T2                          19 (14.8)     20 (10.8)    
   T3                          16 (12.5)     20 (10.8)    
   T4                          14 (10.9)     16 (8.6)     
  N stage                                                 0.526
   N0                          91 (71.1)     143 (76.9)   
   N1                          21 (16.4)     20 (10.8)    
   N2                          10 (7.8)      15 (8.1)     
   N3                          6 (4.7)       8 (4.3)      
  AJCC stage                                              0.346
   I                           86 (67.2)     136 (73.1)   
   II                          29 (22.7)     30 (16.1)    
   III                         13 (10.2)     20 (10.8)    
  WHO classification                                      0.992
   Well differentiated         23 (18.0)     35 (18.8)    
   Moderately differentiated   42 (32.8)     64 (34.4)    
   Poorly differentiated       34 (26.6)     46 (24.7)    
   Signet ring cell            26 (20.3)     36 (19.4)    
   Mucinous                    3 (2.3)       5 (2.7)      
  Lauren classification                                   0.321
   Intestinal                  63 (49.2)     102 (54.8)   
   Diffuse                     62 (48.4)     76 (40.9)    
   Mixed                       3 (2.3)       8 (4.3)      
  Lymphovascular invasion                                 0.268
   Absent                      112 (87.5)    153 (82.3)   
   Present                     16 (12.5)     33 (17.7)    
  Perineural invasion                                     0.842
   Absent                      116 (90.6)    170 (91.4)   
   Present                     12 (9.4)      16 (8.6)     

Data are presented as mean±SD or number (%).

AJCC, American Joint Committee on Cancer; WHO, World Health Organization.

###### 

Univariate Analysis of Overall Survival

  Factor                       No. of patients   10-Year OS rate, %   HR (95% CI)          p-value
  ---------------------------- ----------------- -------------------- -------------------- ---------
  Age, yr                                                                                  0.011
   ≤56                         166               96.3                 Reference            
   \>56                        148               89.2                 3.21 (1.31--7.86)    
  Sex                                                                                      0.736
   Male                        210               92.8                 1.17 (0.48--2.83)    
   Female                      104               93.8                 Reference            
  Tumor size, mm                                                                           0.081
   \<20                        110               98.4                 Reference            
   ≥20                         204               90.3                 2.62 (0.89--7.69)    
  Tumor location                                                                           0.068
   Middle third                119               87.7                 Reference            
   Lower third                 195               96.7                 2.16 (0.94--4.92)    
  WHO classification                                                                       0.882
   Well differentiated         58                93.5                 Reference            
   Moderately differentiated   106               93.0                 0.78 (0.25--2.47)    
   Poorly differentiated       80                91.6                 1.04 (0.33--3.28)    
   Signet ring cell            8                 96.1                 0.63 (0.15--2.63)    
   Mucinous                    62                87.5                 1.77 (0.21--15.22)   
  *H. pylori* status                                                                       0.036
   Positive                    186               95.1                 Reference            
   Negative                    128               91.5                 2.73 (1.07--6.98)    
  T stage                                                                                  0.132
   T1/2                        209               95.2                 Reference            
   T3/4                        105               88.7                 1.88 (0.83--4.28)    
  N stage                                                                                  0.315
   N0                          234               94.4                 Reference            
   N1--3                       80                89.1                 1.56 (0.66--3.71)    

OS, overall survival; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; *H. pylori*, *Helicobacter pylori*.

###### 

Comparison of the Overall Survival and Hazard Ratios for Overall Survival Rate between *Helicobacter pylori*-Negative and *H. pylori*-Positive Gastric Cancer Patients according to Clinicopathologic Factors

  Factor                       10-Year OS rate, %   HR (95% CI)   p-value              
  ---------------------------- -------------------- ------------- -------------------- -------
  Age, yr                                                                              
   ≤56                         96.6                 96.1          1.33 (0.29--6.03)    0.710
   \>56                        93.1                 86.4          3.88 (1.09--13.79)   0.036
  Sex                                                                                  
   Male                        94.1                 91.6          2.28 (0.78--6.71)    0.134
   Female                      97.0                 91.6          4.73 (0.57--39.30)   0.151
  Tumor size, mm                                                                       
   \<20                        96.7                 100.0         3.21 (0.33--31.48)   0.317
   ≥20                         94.4                 86.8          2.68 (0.96--7.48)    0.060
  Tumor location                                                                       
   Middle third                89.7                 86.4          1.47 (0.48--4.53)    0.504
   Lower third                 98.8                 95.0          9.60 (1.19--77.50)   0.034
  WHO classification                                                                   
   Well differentiated         95.2                 92.1          3.29 (0.37--29.52)   0.288
   Moderately differentiated   92.4                 93.3          2.28 (0.44--11.85)   0.326
   Poorly differentiated       94.0                 89.1          2.23 (0.43--11.64)   0.340
   Signet ring cell            100.0                93.0          2.80 (0.22--35.81)   0.428
   Mucinous                    100.0                80.0          42.98 (0.00--)       0.661
  T stage                                                                              
   T1/2                        94.9                 95.6          1.90 (0.57--6.36)    0.300
   T3/4                        95.8                 81.3          4.77 (1.02--22.28)   0.047
  N stage                                                                              
   N0                          95.5                 93.8          2.52 (0.80--8.00)    0.116
   N1--3                       94.6                 82.4          3.35 (0.67--16.84)   0.142

OS, overall survival; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization.

###### 

Multivariate Analysis of Overall Survival

  Factor               HR (95% CI)         p-value
  -------------------- ------------------- --------------------------------------------------
  Age, yr                                  0.017[\*](#tfn6-gnl-11-635){ref-type="table-fn"}
   ≤56                 Reference           
   \>56                3.02 (1.22--7.47)   
  Sex                                      0.835[†](#tfn7-gnl-11-635){ref-type="table-fn"}
   Male                1.10 (0.44--2.74)   
   Female              Reference           
  Tumor size, mm                           0.236[†](#tfn7-gnl-11-635){ref-type="table-fn"}
   \<20                Reference           
   ≥20                 2.03 (0.63--6.57)   
  *H. pylori* status                       0.026[\*](#tfn6-gnl-11-635){ref-type="table-fn"}
   Positive            Reference           
   Negative            2.95 (1.14--7.66)   
  T stage                                  0.319[†](#tfn7-gnl-11-635){ref-type="table-fn"}
   T1                  Reference           
   T2--4               1.68 (0.60--4.70)   
  N stage                                  0.926[†](#tfn7-gnl-11-635){ref-type="table-fn"}
   N0                  Reference           
   N1--3               1.05 (0.37--2.96)   

HR, hazard ratio; CI, confidence interval; *H. pylori*, *Helicobacter pylori*.

Variables with p\<0.05;

Clinically important variables.
